SG Americas Securities LLC Buys New Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

SG Americas Securities LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 13,056 shares of the company’s stock, valued at approximately $156,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OLMA. Janus Henderson Group PLC boosted its stake in shares of Olema Pharmaceuticals by 74.5% in the first quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock worth $13,817,000 after buying an additional 521,562 shares during the last quarter. Entropy Technologies LP purchased a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $161,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Olema Pharmaceuticals during the 1st quarter worth approximately $176,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Olema Pharmaceuticals during the 2nd quarter valued at approximately $945,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Olema Pharmaceuticals in the 2nd quarter valued at $34,753,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, major shareholder Biocapital Advisors L. Paradigm sold 2,400,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $14.91, for a total value of $35,784,000.00. Following the transaction, the insider now owns 783,118 shares in the company, valued at $11,676,289.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 4,066 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.58, for a total value of $63,348.28. Following the completion of the sale, the director now owns 752,217 shares in the company, valued at approximately $11,719,540.86. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Biocapital Advisors L. Paradigm sold 2,400,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $14.91, for a total transaction of $35,784,000.00. Following the completion of the transaction, the insider now directly owns 783,118 shares in the company, valued at $11,676,289.38. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 19.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on OLMA. Oppenheimer restated an “outperform” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Thursday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $11.72 on Friday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $17.79. The company has a fifty day moving average of $12.08 and a two-hundred day moving average of $11.83.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). As a group, sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -1.51 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.